The researchers enrolled DLBCL patients with relapsed or refractory disease who had already received at least two lines of treatment in the phase 2 portion of a phase 1-2 investigation. They concluded that treatment with glofitamab was successful for DLBCL, with more than half of the patients experiencing a grade 3 or 4 adverse event.

Despite being mostly low-grade, cytokine release syndrome, skin-related events, and dysgeusia were frequent side effects of talquetamab therapy. Patients who had multiple myeloma that was relapsed or resistant after receiving substantial prior treatment had a significant response to talquetamab.

Because a growing number of Medicare-eligible patients — currently 48% of 58 million beneficiaries — are enrolled in Medicare Advantage plans, the problem of “no prior authorization” happens increasingly frequently these days. Some medical professionals believe that before their gullible patients switch their coverage, they should make a special effort to inform them of the drawbacks of these plans.

According to a news release from study lead author Colin Haile, a research associate professor of psychology at UH and the Texas Institute for Measurement, Evaluation and Statistics (TIMES) and a founding member of the UH Drug Discovery Institute, “Our vaccine is able to generate anti-fentanyl antibodies that bind to the consumed fentanyl and prevent it from entering the brain, allowing it to be eliminated out of the body via the kidneys.” The person won’t experience the euphoric benefits as a result, and they can “get back on the wagon” to sobriety.

For the treatment of psychosis in schizophrenia, may an oral molecule constitute a new class of psychotropic drug with a non-D2-receptor binding mode of action? The purpose of a recent study was to answer that question, which Dr. Matt Birnholz delves into in this audio abstract.

SEP-363856, a non-D2-receptor binding antipsychotic, reduced the PANSS total score from baseline more than the placebo in this 4-week experiment comprising individuals with acute exacerbations of schizophrenia. Longer and larger trials are required to confirm SEP-363856’s effects and side effects as well as its efficacy in comparison to other medications currently used to treat schizophrenia patients.